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Background and Purpose: There are no medications currently available to treat met-
abolic inflammation. Bruton's tyrosine kinase (BTK) is highly expressed in monocytes
and macrophages and regulates NF-κB and NLRP3 inflammasome activity; both
propagate metabolic inflammation in diet-induced obesity.
Experimental Approach: Using an in vivo model of chronic inflammation, high-fat diet
(HFD) feeding, in male C57BL/6J mice and in vitro assays in primary murine and
human macrophages, we investigated if ibrutinib, an FDA approved BTK inhibitor,
may represent a novel anti-inflammatory medication to treat metabolic inflammation.
Key Results: HFD-feeding was associated with increased BTK expression and activa-
tion, which was significantly correlated with monocyte/macrophage accumulation in
the liver, adipose tissue, and kidney. Ibrutinib treatment to HFD-fed mice inhibited the
activation of BTK and reduced monocyte/macrophage recruitment to the liver, adi-
pose tissue, and kidney. Ibrutinib treatment to HFD-fed mice decreased the activation
of NF-κB and the NLRP3 inflammasome. As a result, ibrutinib treated mice fed HFD
had improved glycaemic control through restored signalling by the IRS-1/Akt/GSK-3β
pathway, protecting mice against the development of hepatosteatosis and proteinuria.
We show that BTK regulates NF-κB and the NLRP3 inflammasome specifically in pri-
mary murine and humanmacrophages, the in vivo cellular target of ibrutinib.
Conclusion and Implications: We provide “proof of concept” evidence that BTK is a
novel therapeutic target for the treatment of diet-induced metabolic inflammation
and ibrutinib may be a candidate for drug repurposing as an anti-inflammatory agent
for the treatment of metabolic inflammation inT2D and microvascular disease.
Abbreviations: ACR, albumin to creatinine ration; BMDM, bone marrow derived macrophage; BTK, Bruton's tyrosine kinase; CLL, chronic lymphatic leukaemia; EMA, European Medicines
Agency; FDA, U.S. Food and Drug Administration; HFD, high fat diet; hMoDM, human monocyte derived macrophage; NLPR3, NLR family pyrin domain containing 3; OGTT, oral glucose
tolerance test; T2D, Type 2 diabetes; TLR, toll-like receptor.
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1 | INTRODUCTION
The worldwide prevalence of obesity has doubled since 1980 with
over 1.9 billion people being considered overweight or obese
(Swinburn et al., 2011). Diet-induced obesity induces a state of
chronic metabolic inflammation (Saltiel & Olefsky, 2017). The control
of energy and metabolism in tissues is directed largely by innate
immune cells, such as macrophages leading to the production of solu-
ble effector molecules including cytokines and chemokines (Tanti,
Ceppo, Jager, & Berthou, 2013). This state of “low-grade” chronic
inflammation predisposes individuals to metabolic syndrome and the
associated co-morbidities that develop over time including insulin
resistance, Type 2 diabetes (T2D), cardiovascular disease and non-
alcoholic fatty liver disease (Lusis, Attie, & Reue, 2008) (Esposito &
Giugliano, 2004).
Immune cell accumulation specifically from the myeloid linage
coupled with the activation of the pathways including those involv-
ing NF-κB and the NLRP3 inflammasome have been heavily impli-
cated in orchestrating the inflammatory response in T2D (Arkan
et al., 2005) (Vandanmagsar et al., 2011). Pharmacological inhibition
or genetic deletion of components of the NF-κB pathway
(i) prevents the development of HFD-induced insulin resistance
(Chiazza et al., 2015) (Benzler et al., 2015) and (ii) slows the progres-
sion of microvascular disease. Equally, inhibition or genetic deletion
of key components the NLRP3 inflammasome reduced systemic
inflammation in models of diet-induced obesity and protected again
the development of peripheral insulin resistance in mice (Chiazza
et al., 2016).
Currently, there are no medicines for T2D that target metabolic
inflammation and/or prevent the development of microvascular com-
plications. One option for generating new treatments for rapid patient
benefit is to repurpose existing U.S. Food and Drug Administration
(FDA) or European Medicines Agency (EMA) approved drugs.
Exploring existing medications that have under-appreciated anti-
inflammatory effects for new indications could be a time- and cost-
effective approach to prevent and/or treat the development of
microvascular complications of T2D. Anti-inflammatory agents have
been shown to be powerful tools to study disease pathophysiology in
preclinical models of T2D. However, to date, little translational
research as followed up on these successes.
Germline mutations in Bruton's tyrosine kinase (BTK) have been
implicated in the primary immunodeficiency disease X-linked
agammaglobulinaemia, through its essential role in B lymphocyte
development (Nyhoff et al., 2018). The first BTK inhibitor to be FDA
approved for clinical use was ibrutinib for the treatment of chronic
lymphatic leukaemia (CLL) (Davids & Brown, 2012). However, BTK
has an additional role in regulating inflammation, being highly
expressed in monocytes/macrophages (Ito et al., 2015). BTK has a
proposed role in signal transduction downstream of several toll-like
receptors (TLR) which results in reduced activation of NF-κB
(Ní Gabhann et al., 2014) and also regulates NLRP3 inflammasome
assembly in macrophages (Ito et al., 2015). Importantly, BTK is not
expressed in hepatocytes or adipocytes, the other cell types responsi-
ble for peripheral insulin resistance (Uhlén et al., 2015) and so has a
specific role in macrophages, the key cell type that drives the produc-
tion of pro-inflammatory mediators that leads to the development of
metabolic syndrome and insulin resistance.
Ibrutinib has therapeutic utility in a number of preclinical
models of human disease; however, most of these models have a
strong B-cell component (Honigberg et al., 2010; Chalmers
et al., 2018). In the present study, we investigated whether treat-
ment with ibrutinib reduces metabolic inflammation in a murine
model of HFD-induced obesity. HFD feeding results in an increase
in macrophage number in peripheral tissues including the liver, adi-
pose tissue, and kidney. We hypothesized that ibrutinib treatment
would target the cells, which express high levels of BTK, namely,
monocytes and macrophages, reducing their pro-inflammatory activ-
ity in vivo. We predicted that inhibition of BTK signalling would
result in decreased activation of both NF-κB and the NLRP3
What is already known
• BTK is a druggable target, with FDA approved medica-
tions available.
What does this study add
• BTK expression and activation are increased in male
C57BL/6J mice fed a high-fat diet.
• Inhibition of BTK in HFD-fed mice decreased macro-
phage NF-κB and NLRP3 inflammasome activity.
What is the clinical significance
• We have identified BTK as a new pathway that is acti-
vated in metabolic inflammation.
• Ibrutinib may represent a novel candidate for drug
repurposing for the treatment of metabolic inflammation.
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inflammasome in mice fed a HFD. We report for the first time that
treatment with a BTK inhibitor results in reduced metabolic inflam-
mation and improved function in the liver, adipose tissue, and
the kidney.
2 | METHODS
2.1 | Animals and human studies
All animal care and experimental protocols in this study was in accor-
dance with the Home Office guidance on Operation of Animals
(Scientific Procedures Act 1986) and were approved by the Animal
Welfare Ethics Review Board (AWERB) of Queen Mary University of
London and the University of Oxford. The study was performed under
licences issued by the Home Office PPL:70/8052 and P144E44F2.
Animal studies are reported in compliance with the ARRIVE guidelines
(Kilkenny et al., 2010) and with the recommendations made by the
British Journal of Pharmacology.
2.1.1 | High-fat diet induced insulin resistance
Ten weeks old male C57BL/6J mice purchased from Charles River
Ltd, housed in the same unit under conventional housing conditions
at 25 ± 2C, were randomly assigned either normal diet (chow) (7%
simple sugars, 3% fat, 50% polysaccharide, 15% protein) or high-fat
diet (HFD) (D12331 diet, Research Diet Inc., USA). All mice had access
to food and water ad libitum. After 6 weeks of dietary manipulation,
mice were randomly assigned to a treatment group receiving either
ibrutinib (3 or 30 mgkg−1, in vehicle) or vehicle alone (5% DMSO,
30% cyclodextrin) for 5 days per week for 6 weeks by oral gavage.
The doses used here are within the range that have previously been
reported to produce selective inhibition of BTK, in a short-term model
of cerebral ischaemia (Ito et al., 2015) and in a chronic model of arthri-
tis (Honigberg et al., 2010). One week prior to the end of the experi-
ment, an oral glucose tolerance test was performed. 24 h before the
end of the experiment, mice were placed in metabolic cages and urine
collected. Blood was collected by cardiac puncture under general
anaesthesia (Ketamine/Xylazine [100 mgkg−1 and 10 mgkg−1; i.p.]
[Centaur Services, UK]).
2.1.2 | XID mice
XID mice (B6.CBA-Btkxid/AllmJ) (Lindsley, Thomas, Srivastava, &
Allman, 2007) are an inbred strain on the CBA background pur-
chased from The Jackson Laboratory (#009361). They have a point
mutation rendering the kinase domain of BTK inactive. Specifically,
there is a C to T substitution at coding nucleotide 82, which alters
the amino acid sequence; substituting an arginine for cysteine.
The substitution is in a conserved PH domain and blocks the
activation of the kinase (Rawlings et al., 1993) preventing BTK
phosphorylation at Tyr223, which is a key activating site. Impor-
tantly, ibrutinib binds irreversibly to Cys481, also in the active site of
the kinase domain and inhibits auto-phosphorylation of Tyr223, thus
blocking BTK activity.
2.2 | Cell culture
2.2.1 | Macrophage reporter cell line (RAW Blue)
A commercially available reporter macrophage cell line (RAW Blue
cells; InvivoGen, San Diego, CA; RRID:CVCL_X594) was used: Briefly,
cells were derived from murine RAW 264.7 macrophages with chro-
mosomal integration of a secreted embryonic alkaline phosphatase
(SEAP) reporter construct, induced by NF-κB and activator protein
1 (AP-1) transcriptional activation. Cells were grown to 80% conflu-
ence in T-25 culture flasks in DMEM containing 4.5 gL−1 glucose,
heat-inactivated 10% FBS, 2 mM L-glutamine, and 200 μgml−1 Zeocin
antibiotic (InvivoGen) at 37C in 5% CO2. To minimize experimental
variability, only cells with fewer than five passages were used. Cells
were plated at 0.95 × 105 per well. After experimental treatment,
20 μl of cell supernatants was added to 180 μl of QuantiBlue sub-
strate (InvivoGen) and incubated at 30C for 60 min, plate was then
read at an OD at 655 nm (OD655) on a microplate spectrophotometer
(PherastarFSX, BMG Lab, UK).
2.2.2 | Murine bone marrow-derived macrophages
(BMDMs)
Bone marrow-derived macrophages were generated as previously
described (Recio et al., 2018). Briefly, fresh bone marrow cells from
tibiae and femurs of male C57BL/6 or XID mice aged 8–10 weeks
werecultured inDMEMcontaining4.5 gL−1 glucose, 2mML-glutamine,
50 unitsml−1 penicillin and 50 μgml−1 streptomycin, 10% heat-
inactivatedFBS,10%L929cell-conditionedmedia (as a sourceofmacro-
phage colony-stimulating factor) and for 7 days. Bonemarrow cellswere
seeded into8mlofmediumin90mmnon-tissueculture treatedPetridis-
hes (ThermoFisherScientific, Sterilin,UK).OnDay5,anadditional5mlof
mediumwas added. Gentle scrapingwas used to lift cells. BMDMswere
then counted and suspended in FBS free media at the desired cell
concentration.
2.2.3 | Human monocyte-derived macrophages
(hMoDMs)
Peripheral blood mononuclear cells (PBMC) were purified from leuko-
cyte cones from healthy volunteers with informed consent (NHSBTS,
Oxford, UK) by density centrifugation over Ficoll-Paque PLUS (Sigma).
The PBMC layer was carefully harvested and then washed twice with
PBS. Monocytes were then isolated from the PBMCs by negative
selection using magnetic beads (Miltenyi Biotec, Bergisch Gladbach,
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Germany). Cells were maintained in RPMI 1640 medium sup-
plemented with 1% human serum, 50 ngml−1 macrophage colony
stimulating factor (hM-CSF, BioLegend), 50 unitsml−1 penicillin and
50 μgml−1 streptomycin for 7 days.
2.3 | Caspase 1 assay
Caspase 1 activity was measured using commercially available kits
(Caspase 1 Glo inflammasome assay, Promega). Briefly, BMDM
(2.5 × 104) were seeded on half area, white walled, 96-well multiwell
plates. BMDM were pretreated with ibrutinib for 1 h prior to 8 h LPS
(100 ngml−1) stimulation. To assay caspase 1 activity, ATP (5 mM)
was added for the last 60 min. Samples (20 μl ) of cell supernatant
were then then incubated with 40 μM Z-WEHD-aminoluciferin
(120 μM) MG-132 inhibitor in Caspase-Glo® 1 Buffer for 1 h.
The luminescence was read with a microplate spectrophotometer
(PherastarFSX, BMG Lab).
2.4 | mRNA expression
Mouse tissues and cultured cells were harvested into TRIzol
reagent (Life Technologies) and total RNA extracted. RNA concen-
tration and quality was determined with a ND-1000 spectropho-
tometer (Nano Drop Technologies, Wilmington, USA). cDNA was
synthesized from 1,000 ng RNA using the QuantiTect Reverse
Transcription kit (Qiagen, Manchester, UK) according to the manu-
facturer's instructions. Real-time quantitative PCR was performed
using Sybr Select gene expression master mix (Life Technologies) in
the StepOnePlus™ thermal cycler (Applied Biosystems). Primers
were purchased from Qiagen (il1β, il18, tnfα, il6, il10, cxcl1, ccl2,
ccl5, btk, CD68, cd38, screb, fasn, ucp2, ctp, lcad, scd1, and βactin).
Cycle threshold values were determined by the StepOne software,
and target gene expression was normalized to housekeeping gene
(β-actin or 18S).
2.5 | Quantification of cytokine level
BMDM or hMoDM (1.5 × 106) were seeded in 6-well plates. BMDM
or hMoDM were pretreated with ibrutinib for 1 h prior to stimulation
with LPS (100 ngml−1) for 8 h. Culture medium was adjusted to
5 mM ATP in the last 60 min to allow secretion of IL-1β.
2.5.1 | ELISA
Measurement of the protein levels of IL-1β, TNFα and IL-6, CXCL1,
CCL2, and CCL5, secreted into cell supernatants from 1.5 × 106
murine BMDMs was performed by ELISA (R&D Systems) according to
the manufacturer's instructions.
2.5.2 | Bead assay
Measurement of protein levels of secreted IL-1β, TNFα, and IL-6 in
cell supernatants from 1.5 × 106 human MoDM's was performed by
Legend Plex multi-analyte assay kit (BioLegend) according to the man-
ufacturer's instruction. Data were acquired using a BD Fortessa X20
cytometer (BD Biosciences) and analysed using LegendPlex Software
(BioLegend).
2.6 | Flow cytometry
Cells were washed in FACS buffer (0.05% BSA, 2 mM EDTA in PBS
pH 7.4) blocked using anti CD16/32 (Biolegend; RRID:AB_312801)
(for 10 min at 4C, followed by antibody staining for the surface
markers BV421-conjugated CD11b (BioLegend; RRID:AB_10897942),
PE-conjugated CD14 (BioLegend; RRID:AB_314187) with appropriate
isotype controls. Data were acquired using a BD Fortessa X20
cytometer (BD Biosciences; RRID:SCR_013311) and then analysed
using FlowJo (Tree Star Inc, USA; RRID:SCR_008520) software.
2.7 | Western blot
The immuno-related procedures used in this study comply with the
recommendations made by the British Journal of Pharmacology
(Alexander et al., 2018). Tissues (liver and kidney) were lysed, as
previously described (Purvis et al., 2017). Briefly, samples (100 mg)
of of snap frozen tissue was suspended in 0.3 ml of RIPA buffer
containing phosphatase and protease inhibitors (Sigma, UK) for
30 mins and cells lysed by mechanical disruption, then centrifuged
at 10,000g for 15 mins at 4 C and the supernatant collected, Pro-
tein concentration was determined by using a BCA protein assay
kit (ThermoFisher Scientific). Total cell protein (30 mg) was added
to 4× Laemmli buffer (250 mM Tris–HCl, pH 6.8, 8% SDS, 40%
glycerol, 0.004% bromophenol blue, 20% β-mercaptoethanol) and
heated at 95C for 5 min. Samples were then resolved on SDS-
PAGE gels and transferred onto Hybond ECL nitrocellulose mem-
branes (GE Healthcare, Buckinghamshire, UK). Membranes were
blocked with 5% BSA (Sigma-Aldrich) in TBS-Tween for 1 h at RT
and then incubated with the primary antibody, mouse anti-Ser473-
Akt (Cell Signaling Technology Cat#4051; RRID:AB_331159), rabbit
anti-total Akt (Cell Signaling Technology Cat#9272; RRID:RRID:
AB_329827), rabbit anti-Ser307-IRS1 (Cell Signaling Technology
Cat# 2385, RRID:AB_330363), mouse anti-total IRS1 (Cell Signaling
Technology Cat# 3194, RRID:AB_561124), rabbit anti-total BTK
(Abcam Cat# ab51204, RRID:AB_868519), rabbit anti-Tyr223 BTK
(Abcam Cat# ab51210, RRID:AB_873714), rabbit anti-total PLCγ
(Cell Signaling Technology Cat# 3860, RRID:AB_1196659), rabbit
anti-Tyr1217 PLCγ (Cell Signaling Technology Cat# 3871, RRID:
AB_2299548), rabbit anti-phospho-Ser9-GSK-3β (Cell Signaling
Technology Cat# 9322, RRID:AB_2115196), rabbit anti-total GSK-3β
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(Cell Signaling Technology Cat# 9315, RRID:AB_490890), mouse anti-
Ser32/36 IKBα (Cell Signaling Technology Cat# 4814, RRID:
AB_390781), mouse anti-total IKBα (Cell Signaling Technology Cat#
9242, RRID:AB_331623), rabbit anti-Ser176/180-IKKα/β (Cell Signaling
Technology Cat# 2697, RRID:AB_2079382), rabbit anti-total IKKα/β
(Cell SignalingTechnology Cat# 2370, RRID:AB_2122154), rabbit anti-
NF-κB (Cell Signaling Technology Cat# 8242, RRID:AB_10859369),
ASC (Cell Signaling Technology Cat# 67824, RRID:AB_2799736),
NLRP3 (Cell Signaling Technology Cat# 15101, RRID:AB_2722591),
gasdermin D (Cell Signaling Technology Cat# 93709, RRID:
AB_2800210), IL-1β (Cell Signaling Technology Cat# 12242, RRID:
AB_2715503) and mouse anti-caspase 1 p20 (AdipoGen Cat# AG-
20B-0042, RRID:AB_2490248) diluted 1:1,000 in 2% BSA/TBS-
Tween overnight at 4C. Next, membranes were incubated with an
HRP-conjugated anti-rabbit (Cell Signaling Technology Cat# 7074,
RRID:AB_2099233) or anti-mouse (Cell Signaling Technology Cat#
7076, RRID:AB_330924) secondary antibody diluted 1:10,000 in 2%
BSA for 1 h at room temperature. Protein bands were visualized by
incubating the membranes for 5 min with Amersham ECL prime and
subsequent exposure to X-ray film over a range of exposure times.
Rabbit anti-β-actin (Cell Signaling Technology Cat# 4970, RRID:
AB_2223172) and rabbit anti-histone 3 (Cell Signaling Technology
Cat# 4499, RRID:AB_10544537) were used as loading control. For
successive antibody incubations using the same membrane bound




For p65 expression and location detection by immunofluorescence,
cells placed in a 4-well chamber-slide were fixed (4% paraformalde-
hyde) for10minat roomtemperature, permeabilized (0.5%TritonX-100
in PBS) for 10min at 4C, blockedwith 4%BSA/PBS containing 6%don-
key serum, and incubated with mouse anti-p-65 antibody diluted (Cell
Signaling Technology Cat# 8242, RRID:AB_10859369) 1:100 in 4%
BSA/PBS, overnight at 4C.Cellswere then incubatedwith donkey anti-
mouse Alexa Fluor 488 (Thermo Fisher Scientific Cat# A-11034, RRID:
AB_2576217) (diluted1:500 in4%BSA/PBSfor1hourat roomtempera-
ture. DAPIwas used for nuclear counterstaining. The slidewasmounted
with Fluormount-G®, and cells were visualized using a confocal
microscope.
2.8.2 | Oil Red O staining
Frozen liver samples were embedded in OCT and cut in 10 μm sec-
tions. Sections were brought to room temperature, fixed with 10%
buffer formalin for 5 min, washed with 60% isopropanol, then satu-
rated with Oil Red O (1% w/v, 60% isopropanol) for 15 min, washed
in 60% isopropanol and rinsed in distilled water. Then sections were
then mounted in aqueous mounting medium with coverslips. Images
were acquired using a NanoZoomer Digital Pathology Scanner
(Hamamatsu Photonics K.K., Japan) and analysed using the NDP
Viewer software.
2.8.3 | Periodic acid Schiff's staining
Kidney samples were obtained at the end of the experiment and fixed
in 10% neutral-buffered formalin for 48 h, and histology staining was
performed. Briefly, kidney tissue was embedded in paraffin and
processed to obtain 4 μm sections. After deparaffinization, sections
were rehydrated through graded alcohol to distilled water. The sec-
tions were then incubated to saturation in periodic acid Schiff's solu-
tion (Sigma, UK) for 30 min and washed in distilled water. Then
sections were then dehydrated through graded alcohols and cleared
before mounting with coverslips. Images were acquired using a
NanoZoomer Digital Pathology Scanner and analysed using the NDP
Viewer software (Purvis et al., 2019).
2.8.4 | Immunohistochemistry
Kidney sections cut at 4 μm were deparaffinized to PBS. Antigen
retrieval was performed by in citrate buffer (pH 6.0) for 15 min. Once
cooled, sections were incubated with 3% H2O2 for 20 min to inacti-
vate endogenous peroxidases (Dako EnVision+ System-HRP-DAB,
K4010) and subsequently treated with 10% normal goat serum (Dako,
UK) to reduce non-specific absorption. Sections were subsequently
incubated at 37C for 1 h with the following primary antibodies: anti-
F4/80 (Abcam Cat# ab111101, RRID:AB_10859466) washed with
PBS and then incubated at room temperature for 30 min with labelled
polymer-HRP antibody (Dako EnVision+ System, HRP-DAB). Sections
were developed in DAB chromogen solution, and the reaction
stopped by immersion of sections in water. Counterstaining was per-
formed with Harris haematoxylin before sections were dehydrated
and mounted in DPX mounting medium.
2.9 | Data and statistical analysis
The data and statistical analysis comply with the recommendations of
the British Journal of Pharmacology on experimental design and analy-
sis in pharmacology (Curtis et al., 2018). All experiments were
designed, where possible, to generate groups of equal size. Power cal-
culations were used to estimate the group size based on an expected
effect size of 30%. Where possible, blinding and randomisation proto-
cols were used. All data in the text and figures are presented as
mean ± standard error mean (SEM) of n observations, where n repre-
sents the number of animals studied (in vivo) or independent values,
not technical replicates (in vitro). For western blot data, all data are
represented as fold change to mean control (normal chow diet). All
statistical analysis was calculated using GraphPad Prism 7 for Mac
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(GraphPad Software, San Diego, California, USA; RRID:SCR_002798).
Statistical analysis was only undertaken for studies where each group
size was at least n = 5. For western blot analysis, some representative
data are shown where group size is less then n = 5. When the mean of
two experimental groups were compared, a two-tailed Students t-test
was performed. Normally distributed data without repeated measure-
ments were assessed by a one-way ANOVA followed by Bonferroni
correction if the F value reached significance. In all cases a P < 0.05
was deemed significant.
2.10 | Data and resource availability
The datasets generated during and/or analysed during the current
study are available from the corresponding author upon reasonable
request. No novel resources were generated during the current study.
2.11 | Materials
Ibrutinib (Cambridge BioScience, UK); LPS (Lipopolysaccharides from
Escherichia coli O111:B4, Sigma, UK), general anaesthetic used.
2.12 | Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to
corresponding entries in the IUPHAR/BPS Guide to PHARMACOLOGY
(http://www.guidetopharmacology.org) and are permanently archived
in the Concise Guide to PHARMACOLOGY 2019/20 (Alexander,
Fabbro, et al., 2019a, b; Alexander, Kelly, et al., 2019a, b).
3 | RESULTS
3.1 | Treatment with ibrutinib reduces the diabetic
phenotype in a murine model of HFD feeding
C57BL/6J mice were fed either chow or HFD for 6 weeks and then
treated with ibrutinib (3 or 30 mgkg−1; p.o.; five times per week) or
vehicle for a further 6 weeks. At the time of treatment, mice fed a
HFD had developed a small, but significant, augmentation in oral glu-
cose tolerance test (OGTT) (Figure S1A, B). Importantly, by week
12 of HFD feeding, control mice fed a HFD gained more weight than
mice fed a chow diet, specifically they gained more fat mass (Table 1).
Chronic treatment with ibrutinib (3 or 30 mgkg−1) to chow or HFD-
fed mice did not alter calorific intake, weight gain or cause hepatocel-
lular damage (Figure S1C–F; Table 1). When compared to mice fed a
chow diet, mice fed a HFD and treated with vehicle exhibited a signifi-
cant elevation in fasting blood glucose (values at time=0; Figure 1a)).
Mice fed a HFD and treated with either 3 or 30 mgkg−1 ibrutinib had
significantly lower fasting blood glucose, compared with that in mice
fed a HFD and treated with vehicle (values at time=0; Figure 1a).
When compared to mice fed a chow diet that underwent an oral glu-
cose tolerance test (OGTT), mice fed a HFD exhibited a significant
and prolonged elevation in blood glucose levels (Figures 1a, b). HFD
mice also had elevated terminal plasma insulin levels (Figure 1c) and
non-fasting blood glucose (Figure 1d). Mice fed a HFD and treated
with either 3 or 30 mgkg−1 ibrutinib displayed no significant change
in OGTT when compared to chow fed mice (Figure 1a,b), and signifi-
cantly lower plasma insulin levels (Figure 1c) and non-fasting blood
glucose (Figure 1d) when compared to mice fed a HFD treated with
vehicle. Taken together, these results suggest that mice fed a HFD
and treated with ibrutinib have improved glycaemic regulation.
TABLE 1 Basic metabolic parameters measured in interventional study
Having demonstrated that treatment with ibrutinib improved
functional parameters of glycaemic regulation in HFD fed mice, we
next investigated the effects of ibrutinib treatment on the insulin
signalling pathway in the liver. When compared to mice fed a chow
diet, mice fed a HFD treated with vehicle have an increase in the
phosphorylation on Ser307 of IRS-1 (Figure 1e,f), resulting in a reduc-
tion in phosphorylation of downstream mediators Akt on Ser473 and
GSK-3β on Ser9 (Figure 1e,f). Mice fed a HFD and treated with
ibrutinib demonstrated decreased phosphorylation of Ser307 of IRS-1,
attenuating the decrease in phosphorylation of Akt and GSK-3β, com-
pared with mice fed a HFD (Figure 1e,f). Thus, the observed
TABLE 1 Basic metabolic parameters measured in interventional study
Chow
Chow + ibrutinib
(30 mgkg−1) HFD + Veh
HFD + ibrutinib
(3 mgkg−1) HFD + ibrutinib (30 mgkg−1)
Body weight (g) 31.24 ± 0.43* 30.65 ± 0.51* 36.1 ± 0.80 33.55 ± 0.79 31.21 ± 0.31
Weight gain from baseline (g) 7.03 ± 0.54* 6.84 ± 1.85* 11.22 ± 0.51 9.42 ± 0.508 9.91 ± 0.83
Kidney weight (g) 0.3088 ± 0.007 0.3362 ± 0.002 0.3295 ± 0.011 0.3198 ± 0.010 0.3029 ± 0.007
Liver weight (g) 1.185 ± 0.038* 1.187 ± 0.065* 2.817 ± 0.048 1.256 ± 0.048* 1.287 ± 0.0442*
Inguinal fat weight (g) 0.394 ± 0.043* 0.3837 ± 0.003* 0.4531 ± 0.037 0.3505 ± 0.089* 0.3993 ± 0.028*
ALT (UL−1) 45.40 ± 19.95 46.00 ± 11.68 61.04 ± 13.16 58.47 ± 9.031 54.63 ± 7.16
AST (UL−1) 80.88 ± 5.887* 92.01 ± 22.67 120.4 ± 16.55 115 ± 11.87 119 ± 12.18
Body weight, body weight gain from baseline, inguinal fat weight, kidney weight, liver weight, inguinal fat weight, ALT, and AST were measured in mice fed
a standard diet (chow) or a high-fat diet (HFD) for 12 weeks. HFD mice were treated with either vehicle or ibrutinib (3 or 30 mgkg−1 p.o.) five times per
weeks between weeks 7 and 12. Data are expressed as mean ± SEM from 9/10 mice per group.
*P < 0.05, significantly different from HFD + Veh. one-way ANOVA with Bonferroni post hoc test.
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F IGURE 1 Ibrutinib treatment restored insulin signalling through IRS-1/Akt/GSK-3β in mice fed a HFD. (a) Oral glucose tolerance (OGTT)
was assessed over 120 min, 1 week prior to harvest. (b) The AUC of OGTT was calculated for respective groups and used for statistical analysis.
(c) Plasma insulin levels were measured in plasma isolated from whole blood at harvest. (d) Basal, non-fasted, blood glucose was measured at
week 11 1 h prior to harvest. Data shown are (in a) means ± SEM in b, c, d, with individual values; n = 9-10 per group. *P < 0.05, significantly
different from HFD + Veh; one-way ANOVA with Bonferroni post hoc test. (e) Representative western blots for phosphorylation of Ser307 on
IRS-1 in the liver and normalized to total IRS-1; for phosphorylation of Ser473 on Akt in the liver and normalized to total Akt; for phosphorylation
of Ser9 on GSK-3β in the liver and normalized to total GSK-3β and (f) quantified using densitometry. Data shown are individual values with
means ± SEM; n = 3–6 per group. *P < 0.05, significantly different from HFD + Veh; one-way ANOVA with Bonferroni post hoc test.
(g) Representative images of hepatic lipid deposition assessed by Oil Red-O staining and (h) quantified. Scale bars measure 50 μm. Inset images
are 4× digital zoom. (i) Relative gene expression of CD36, SCREB, UCP2, and FASN were assessed by qPCR and normalized to 18S. (j) Relative gene
expression of CTP, LCAD, and SCD1 were assessed by qPCR and normalized to 18S. and gene expression data. Data shown are individual values
with means ± SEM; n = 6 per group. *P < 0.05, significantly different from HFD + Veh; one-way ANOVA with Bonferroni post hoc test
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improvement in glycaemic regulation in ibrutinib treated HFD-fed
mice resulted from preserved insulin signalling through IRS-1/
Akt/GSK-3β.
HFD feeding to mice is associated with the development of
hepatosteatosis in mice. We therefore quantified fat deposition in
the liver using Oil Red O staining. When compared to chow diet,
mice fed a HFD and treated with vehicle had a significant increase
in Oil Red O staining in the liver (Figure 1g,h). Treatment of HFD
fed mice with ibrutinib (3 or 30 mgkg−1) resulted in a significant
reduction in Oil Red O staining in the liver (Figure 1g,h), demon-
strating less lipid deposition in the liver and hence reduced hepatic
steatosis compared to vehicle treated controls. We next wanted to
investigate the expression of genes involved in hepatic lipid
processing. Mice fed a HFD had increased expression of genes
that participate in free fatty acid uptake (CD36, SCREB, UCP2, and
FASN) as well as genes involved in beta oxidation of free fatty
acids (CPT, LCAD, and SCD1) (Figure 1i). Treatment with ibrutinib
attenuated the increase in expression of gene associated with FFA
uptake and beta oxidation (Figure 1i,j) and could account in part
for the reduced lipid accumulation seen in mice fed a HFD and
treated with ibrutinib.
A critical step in the initiation of hepatic lipid uptake and in the
development of diabetes is the accumulation and activation of
immune cells within tissues including the liver. Mice fed a HFD have
increased levels of chemokines (CXCL1, CCL2, and CCL5) mRNA
expression in liver tissue (Figure 2a), which was coupled with
increased immune cell infiltration. Ibrutinib treatment to mice fed a
HFD resulted in reduced monocyte/macrophage chemokine expres-
sion (Figure 2a) and reduced immune cell infiltration (Figure 2e). In the
liver, we observed an increased expression of CD68 (a gene marker
predominantly expressed in macrophages) in mice fed a HFD
(Figure 2b) directly correlated with a significant increase in expression
of BTK (Figure 2c,d). Treatment of HFD fed mice with ibrutinib (3 or
30 mgkg−1) resulted in a significant decrease in expression of CD68
and BTK in the liver (Figure 2b–d) suggesting less infiltration of
inflammatory monocytes/macrophages.
F IGURE 2 Ibrutinib treatment
reduces inflammatory cell recruitment
in the liver of mice fed a HFD.
(a) Relative gene expression of CXCL1,
CCL2, and CCL5 were assessed by
qPCR and normalized to 18S. Relative
gene expression of CD68 (b) and BTK
(c) were assessed by qPCR and
normalized to 18S in the liver.
(d) Correlation of relative gene
expression of CD68 to BTK in the
liver. Correlation was calculated by
linear regression including 95%
confidence intervals. (e) Immune cell
infiltration was assessed by H&E
staining. Inset images are 4× digital
zoom. Data shown are individual
values with means ± SEM. *P < 0.05,
significantly different from
HFD + Veh; one-way ANOVA with
Bonferroni post hoc test
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3.2 | Inhibition of BTK with ibrutinib reduces
inflammation in the liver of HFD fed mice
We next wanted to investigate if the improvements in the diabetic
phenotype seen in mice treated with ibrutinib could be attributed to
reduced activation of pro-inflammatory pathways in the liver. BTK
has been implicated in pro-inflammatory signalling; therefore,
inhibiting BTK in infiltrating monocytes/macrophages could protect
against the development of insulin resistance, through reduced pro-
duction of soluble inflammatory mediators. When compared to mice
fed chow diet, liver tissue from mice fed a HFD exhibited a signifi-
cant increase in the phosphorylation of Tyr223 and hence activation
of BTK (Figure 3a,b), resulting in increased downstream signalling
through PLCγ (Figure 3a,b). Mice fed a HFD treated with ibrutinib
have significantly reduced activation of BTK and downstream effec-
tor PLCγ (Figure 3a,b).
Two of the key pathways involved in the initiation and progres-
sion of metabolic inflammation in the liver are the NF-κB pathway
and the NLRP3 inflammasome. Therefore, we investigated whether
inhibition of BTK with ibrutinib would result in reduced activation
of these two critical signalling pathways in the liver. Firstly, we
examined NF-κB signalling. When compared to mice fed chow diet,
liver tissue from mice fed a HFD exhibited a significant increase in
the phosphorylation of Ser32/36 in IκBα and, hence, activation (phos-
phorylation) of the IKK complex (Figure 3c,e), allowing for increased
nuclear translocation of the NF-κB subunit p65 to the nucleus
where its acts a nuclear transcription factor (Figure 3d,e). Indeed,
we observed increased cytokine mRNA expression (IL-1β, IL-18,
TNFα, and IL-10) (Figure 3f). Liver tissues from mice fed a HFD and
treated with ibrutinib showed a significant reduction in the degree
of phosphorylation of IκBα on Ser32/36 and, hence, reduced activa-
tion of the IKK complex (Figure 3c,e) and as a consequence reduced
nuclear translocation of the p65 NF-κB subunit to the nucleus
(Figure 3d,e). As a result, ibrutinib treatment of mice fed a HFD
attenuated the increase in the gene expression of IL-1β, IL-18,
TNFα, and IL-10 in the liver (Figure 3f).
Secondly, we examined NLRP3 function in liver tissues. Mice
fed a HFD demonstrated assembly of the NLRP3 inflammasome in
the liver, allowing for the sequential proteolytic cleavage of
gasdermin D, and caspase-1, ultimately producing mature IL-1β
(Figure 3g,h). Mice fed a HFD and treated with ibrutinib have sig-
nificantly reduced formation of the NLRP3 inflammasome and,
hence, reduced proteolytic cleavage of pro-gasdermin D and pro-
caspase 1 in the liver resulting in attenuated formation of active
IL-1β (Figure 3g,h). Collectively, these results demonstrate that
chronic treatment with ibrutinib inhibits BTK activity and reduces
NF-κB activation and formation of the NLRP3 inflammasome in
the liver, thus reducing hepatic pro-inflammatory gene expression
and cytokine production. Reducing hepatic inflammation, in
part, protects against the development of peripheral insulin
resistance in mice fed a HFD (Saltiel & Olefsky, 2017; de Luca &
Olefsky, 2008).
3.3 | Treatment with ibrutinib reduces inflammation
in adipose tissue of HFD fed mice
Following HFD feeding, there is a significant expansion of peripheral
adipose tissue deposits that is typically associated with an increase in
the adipose monocyte/macrophage population. Mice fed a HFD had
significantly larger fat pads compared to chow fed mice as expected
(Table 1). Treatment with ibrutinib attenuated the increases in weight
of inguinal and epididymal fat pads compared to vehicle treated con-
trol (Table 1). We also show that mice fed a HFD have high expression
of monocyte/macrophage chemoattractants (CXCL1, CCL2, and
CCL5) in the epididymal fat and in the inguinal fat pads (Figure 4a,c),
which was attenuated by ibrutinib treatment (Figure 4a,c). Within the
adipose tissue, there was an increased expression of CD68 in mice
fed a HFD (Figure 4b,d), and this positively correlated with a signifi-
cant increase in expression of BTK (Figure 4b,d), indicative of
increased macrophage content. Treatment of HFD mice with ibrutinib
(3 or 30 mgkg−1) resulted in significantly decreased expression of
CD68 and BTK in the adipose tissue (Figure 4b,d) suggesting less infil-
tration of inflammatory monocytes/macrophages.
3.4 | Treatment with ibrutinib reduces inflammation
in the kidney of HFD fed mice
Metabolic inflammation coupled with hyperglycaemia leads to the
development of microvascular complications including diabetic
nephropathy. Mice fed a HFD (treated with vehicle) had an increased
urinary albumin to creatinine ratio (ACR), compared to mice fed a
chow diet (Figure 5a). This is a key pathophysiological read out for
proteinuria and a hallmark of early stage diabetic nephropathy
(Figure 5a). This was accompanied by classical histological changes in
the kidney that are consistent with the development of microvascular
disease i.e. glomerular hypertrophy, thickening of the basement mem-
brane and loss of brush borders at the level of the S1–S2 segment of
the proximal convoluted tubules (Figure 5b). Prolonged treatment of
HFD fed mice with ibrutinib (3 or 30 mgkg−1) attenuated both the
proteinuria and the associated histological signs of glomerular and
tubular degeneration (Figure 5a,b). Infiltration of inflammatory macro-
phages is a common finding in diabetic nephropathy. We show that
mice fed a HFD have high expression of the monocyte/macrophage
chemoattractants (CXCL1, CCL2, and CCL5) (Figure 5c) and an
increased number of F4/80+ macrophages in the kidney which was
attenuated by ibrutinib treatment (3 or 30 mgkg−1) (Figure 5e,f).
Additionally, increased expression of macrophage marker CD68
(Figure 5d) was associated with an increase in expression of BTK,
suggesting the primary source of increased BTK is from infiltrating
monocytes and macrophages (Figure 5g). Kidney tissues from mice
fed a HFD exhibited a significant increase in the phosphorylation of
Tyr223 on BTK, suggesting increased activation of BTK, resulting in an
increase downstream tyrosine phosphorylation of PLCγ demonstrat-
ing that BTK is activated and signalling in the diabetic kidney
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F IGURE 3 Ibrutinib treatment reduces inflammation in the liver of mice fed a via inhibition of NF-κB and the NLRP3 inflammasome.
(a) Representative western blots for phosphorylation of Tyr223 on BTK in the liver and normalized to total BTK; for phosphorylation of Tyr1217 on
PLCγ in the liver and normalized to total PLCγ and (b) quantified using densitometry. (c) Representative western blots for phosphorylation of
Ser32/36 on IKBα in the liver and normalized to total IKBα; for phosphorylation of Ser176/180 on IKKα in the liver and normalized to total IKKα;
(d) nuclear translocation of p65 and (e) quantified using densitometry. Data shown are individual values with means ± SEM; n = 3–6 per group.
*P < 0.05, significantly different from HFD + Veh; one-way ANOVA with Bonferroni post hoc test. (f) Relative gene expression of IL-1β, IL-18,
TNFα, and IL-10 were assessed by qPCR and normalized to 18S. (g) Representative western blots for NLRP3 inflammasome assembly, ASC,
formation of gasdermin, the proteolytic cleavage of pro-caspase 1 to caspase 1 and formation of IL-1β normalized to β-actin and (h) quantified
using densitometry. Data shown are individual values with means ± SEM; n = 6–10 per group. *P < 0.05, significantly different from HFD + Veh;
one-way ANOVA with Bonferroni post hoc test
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(Figure 5h,i). Mice fed a HFD and treated with ibrutinib have signifi-
cantly reduced activation of BTK and downstream effector PLCγ.
Taken together, these results suggest that increased macrophage
accumulation in the kidney could be the source of increased BTK acti-
vation seen in kidney of mice fed a HFD.
Activation of both NF-κB and the NLPR3 inflammasome have
been associated with macrophage accumulation and progression of
diabetic nephropathy. Critically, ibrutinib treatment attenuated the
activation of both the NF-κB (Figure S2A, B) and NLRP3
inflammasome activity (Figure S2C, D) in the kidney of mice fed a
HFD. Our data demonstrate that oral dosing with ibrutinib inhibits
BTK signalling protecting against the development of proteinuria by
reducing immune cell recruitment and inhibiting pro-inflammatory
gene expression and cytokine production through its effects on NF-
κB and the NLRP3 inflammasome.
3.5 | Ibrutinib treatment reduces NF-κB and NLRP3
inflammasome activation in murine and human
macrophages
Macrophages are hypothesized to be a key cell type involved in
the local amplification of metabolic inflammation in peripheral
tissues following HFD feeding in this study. Therefore, we wanted
to directly confirm that ibrutinib inhibits the activation of both NF-
κB and the NLRP3 inflammasome in macrophages. To investigate
this, we first used a macrophage cell line stably transfected with a
secreted alkaline phosphatase reporter gene under the transcription
regulation of NF-κB. Macrophages stimulated with LPS for 6 h
exhibited a strong induction of NF-κB activity (Figure 6a) which
could be inhibited when macrophages were pre-incubated with
ibrutinib (1–30 μM) to inhibit BTK 60 min before LPS stimulation
F IGURE 4 Ibrutinib
treatment reduces inflammation
in adipose tissue of mice fed a
HFD. Relative gene expression of
CXCL1, CCL2, and CCL5 were
assessed by qPCR and
normalized to 18S in epididymal
(a) and inguinal (c) adipose
tissues. Relative gene expression
of CD68 and BTK were assessed
by qPCR and normalized to 18S
in the liver. Data shown are
individual values with
means ± SEM. n = 6 per group.
*P < 0.05, significantly different
from HFD + Veh; one-way
ANOVA with Bonferroni post
hoc test. Correlation of relative
gene expression of CD68 to BTK
in epididymal (b) and inguinal
(d) adipose tissues. Correlation of
BTK and CD68 mRNA levels.
Correlation was calculated by
linear regression including 95%
confidence intervals
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F IGURE 5 Ibrutinib treatment prevents the development proteinuria in mice fed a HFD. (a) Urinary albumin to creatinine ratio (ACR).
(b) Kidney sections were stained with periodic acid Schiff staining to assess histological changes. in vivo data (n = 9–10 per group) (c) Relative
gene expression of CXCL1, CCL2, CCL5, and CD68 was assessed by qPCR and normalized to 18S. Data shown are individual values with
means ± SEM; n = 5–6 per group. *P < 0.05, significantly different from HFD + Veh; one-way ANOVA with Bonferroni post hoc test. (f)
Macrophage infiltration was assessed by immunohistochemical staining for macrophage marker F4/80 and quantified (e); scale bars measure
50 μm. Inset images are 4× digital zoom. Data shown are individual values with means ± SEM; n = 8–10 per group. *P < 0.05, significantly
different from HFD + Veh; one-way ANOVA with Bonferroni post hoc test. (g) Relative gene expression of BTK was assessed by qPCR and
normalized to 18S. Data shown are individual values with means ± SEM; n = 5–6 per group. *P < 0.05, significantly different from HFD + Veh;
one-way ANOVA with Bonferroni post hoc test. (h) Representative western blots for phosphorylation of Tyr223 on BTK in the kidney and
normalized to total BTK; for phosphorylation of Tyr1217 on PLCγ in the kidney and normalized to total PLCγ and (i) quantified using densitometry.
Data shown are individual values with means ± SEM; n = 3–6 per group. *P < 0.05, significantly different from HFD + Veh; one-way ANOVA with
Bonferroni post hoc test
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(Figure 6a). No cytotoxicity was observed in macrophages treated
with up to 30 μM of ibrutinib for 9 h in an MTT assay
(Figure S3A). We then confirmed that BTK inhibition with ibrutinib
resulted in less NF-κB activation in primary murine bone marrow
derived macrophages (BMDM) (Figure S3B). LPS stimulation
induced translocation of p65 from the cytoplasm to the nucleus in
BMDM, which was inhibited by pretreatment with ibrutinib
(10 μM; for 1 h prior to LPS stimulation; Figure 6b). Stimulation
of BMDMs with LPS also resulted in the up-regulation of pro-
inflammatory gene expression including IL-1β, IL-18, TNFα, and
IL-6, which was reduced by pre-treating with ibrutinib, in a dose-
dependent manner (Figure S3C).
Next, we demonstrated BTK inhibition with ibrutinib blocked the
formation of the NLRP3 inflammasome in primary murine BMDM
using a caspase-1 activity assay. Incubating BMDMs with LPS alone
does not result in activation of caspase-1 (Figure 6c,) as a second sig-
nal is required. To provide this second stimulus, ATP (5 mM) was
added to BMDM in the last 60 min of LPS challenge, which resulted in
a significant increase in caspase-1 activity (Figure 6c). Pretreatment of
BMDM with ibrutinib (1–30 μM) 60 min prior to LPS + ATP stimula-
tion resulted in a dose-dependent inhibition of caspase-1 activity
(Figure 6c).
The downstream effects of reduced NF-κB (TNFα) and NLRP3
inflammasome (IL-1β) on pro-inflammatory cytokine secretion by
BMDM were also confirmed. BMDM were stimulated with LPS for
8 h and supernatants collected and cytokine levels measured by
ELISA; for IL-1β secretion, ATP was added in the last 60 min. Pre-
treatment with ibrutinib 60 min prior to LPS stimulation significantly
inhibited the secretion of pro-inflammatory cytokines IL-1β and TNFα
in a dose-dependent manner (Figure 6d,f) by macrophages. To confirm
that the effect of ibrutinib was BTK specific, BMDM from WT and
XID mice (which have an inactive BTK) were treated with LPS to mea-
sure TNFα production and LPS + ATP to measure IL-1β production.
Importantly, we demonstrate that TNFα and IL-1β production from
XID mice BMDM was significantly reduced (Figure 6e,g). These exper-
iments demonstrate a clear role for BTK in regulating both NF-κB and
F IGURE 6 Ibrutinib treatment reduces NF-κB and NLRP3 activation in macrophages. (a) NF-κB and AP1 activity assay in RAW Blue cells.
Data shown are individual values with means ± SEM; n = 4 independent experiments. (b) Bone marrow derived macrophages (BMDMs)
pretreated with ibrutinib (10 μM) prior to LPS (0.1 μgml−1) stimulation 30 min followed by p65 staining. Confocal microscopy images are
illustrative of two separate experiments; all images were captured at magnification 60×. (c) Caspase 1 activity was measured using luminescence.
Data shown are individual values with means ± SEM; n = 4 independent BMDM preparations. (d, f) Cytokine (IL-1β and TNFα) secretion
measured by ELISA in WT BMDM. Summary data of n = 6 independent BMDM preparations. (e, g) Cytokine (IL-1β and TNFα) secretion measured
by ELISA in BMDM from WT and XID. Data shown are individual values with means ± SEM; n = 6 independent BMDM preparations. (h) Human
monocytes are isolated from leukocyte cones and purified by magnetic bead purification. Representative flow cytometry plots showing monocyte
enrichment; monocytes are defined as CD14+/CD16. (i) Cytokine secretion (IL-1β and TNFα) was assessed by Bead based ELISA kit and relative
gene expression of IL-1β and TNFα were assessed by qPCR and normalized to 18S. *P < 0.05, significantly different from HFD + Veh; one-way
ANOVA with Bonferroni post hoc test
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NLPR3 inflammasome-dependent cytokine production and secretion
in macrophages.
To test the translational relevance of our findings obtained in murine
macrophages, we studied the activation of pro-inflammatory gene
expression and the secretion of pro-inflammatory cytokines in human
monocyte derived macrophages (hMoDM). Human monocytes were iso-
lated from leukocyte cones obtained from healthy volunteers and
enriched by column separation (Figure 6h) and then differentiated into
macrophages. On Day 7 of differentiation, hMoDM were pretreated
with LPS to induce inflammatory gene expression. Pretreatment with
ibrutinib (10 μM) 60 min prior to LPS stimulation inhibited the increase
in pro-inflammatory gene expression (IL-1β and TNFα) and cytokine
secretion seen in hMoDM treated with LPS alone (Figure 5i,j). Pre-
treatment with ibrutinib prior to LPS stimulation significantly inhibited
the secretion of both NF-κB and NLRP3 dependent cytokines TNFα and
IL-1β in a dose dependant manner (Figure 6i,j). These experiments clearly
demonstrated that inhibition of BTK with ibrutinib had potent anti-
inflammatory effects in human macrophages, resulting from the inhibi-
tion of both NF-κB and NLRP3 inflammasome activity.
4 | DISCUSSION
In this study, we showed for the first time that BTK was activated as a
result of HFD feeding in a model of diet-induced metabolic inflamma-
tion. BTK has previously been shown to regulate pro-inflammatory
pathways including NF-κB and the NLRP3 inflammasome. We, there-
fore, set out to investigate if the anti-cancer agent ibrutinib could
represent a novel drug repositioning opportunity for the treatment of
HFD induced metabolic inflammation. The main findings of this
preclinical study are that chronic treatment of mice fed a HFD with
ibrutinib inhibits the activation and downstream signalling of BTK and
inhibits the activation of NF-κB and the NLRP3 inflammasome in the
liver and kidney. Reduced metabolic inflammation in the liver and
adipose tissue resulted in improved glycaemic control via restoration
of IRS-1/Akt/GSK-3β signalling pathway in the liver. These improve-
ments in glycaemic control were independent of changes in body
weight or calorific intake. Importantly, treatment with ibrutinib also
protected mice from the development of hepatosteatosis and
proteinuria. We demonstrated that the expression of BTK significantly
correlated with expression of CD68 a marker of infiltrating
monocytes/macrophages, while ibrutinib treatment significantly
reduced the expression of monocyte/macrophage chemoattractants
in the liver, adipose, and kidney. We also showed, in primary murine
and human macrophages, that ibrutinib treatment reduced LPS-
stimulated NF-κB activation and attenuated caspase-1 activity,
resulting in a reduction in pro-inflammatory gene expression and a
reduction in secreted cytokines (IL-1β and TNFα). Critically, our work
has identified a novel therapeutic arget in diet induced inflammation,
namely, monocyte/macrophage expressed BTK. Importantly, we
provide “proof-of-concept” data that ibrutinib reduces HFD-induced
inflammation and could be a candidate for repurposing to treat
inflammation in metabolic diseases.
Identifying that monocytes/macrophages are another leukocyte
where BTK is highly expressed broadens interest in this molecule both
in metabolic inflammation and potentially in other inflammatory dis-
eases. BTK expression was positively correlated with expression of
CD68 a monocyte/macrophage marker in mice fed a HFD, suggesting
that the increase in BTK seen in the diabetic liver, adipose tissue, and
kidney is from infiltrating monocytes/macrophages. We suggest that
systemic ibrutinib treatment in vivo inhibited cellular BTK activation
in macrophages of the liver and kidney. The activation of BTK and the
subsequent signalling cascade starts with the phosphorylation of BTK
at Tyr223 which then phosphorylates PLCγ at Tyr1217 (O'Riordan
et al., 2019). In our model, mice fed a HFD exhibited increased phos-
phorylation of BTK in the liver and kidney and that this activation was
inhibited with ibrutinib treatment. We hypothesized that BTK/PLCγ
signalling may regulate both the NF-κB signalling and the activation of
the NLRP3 inflammasome. Previous studies have shown a mechanistic
link between PLCγ activation and NF-κB activity in B-cells (Moscat,
Diaz-Meco, & Rennert, 2003), but no such link had been described in
cells of the myeloid lineage. In our model, we showed that, in primary
murine macrophages, BTK regulated both NF-κB and NLRP3
inflammasome activity, possibly through PLCγ.
Myeloid cell activation in the liver and adipose tissue has been
consistently shown to be the key driver of metabolic inflammation
resulting in increased activation of numerous pathways including
NF-κB. Interventional studies have reported the beneficial effects of
NF-κB inhibition on the development of insulin resistance (Chiazza
et al., 2015; Zhu, Han, Yuan, Xue, & Pang, 2018; Benzler et al., 2015).
Mice with myeloid specific deletion of IKK-β fed a HFD do not
develop insulin resistance, while mice fed a HFD with hepatocyte
specific deletion of IKK develop less severe insulin resistance (Arkan
et al., 2005; Ke et al., 2015). However, deletion of NF-κB activity in
skeletal muscle does not protect mice from the development of insulin
resistance (Röhl et al., 2004). Taken together these published studies
demonstrate that while systemically inhibiting the NF-κB pathways
does prevent the development of insulin resistance, it is the myeloid
specific inhibition that is the critical cellular target in vivo. We would
postulate that the BTK expressed in monocytes/macrophages
within metabolic tissues (liver, adipose tissue and kidney) is the
pharmacological target of ibrutinib, because BTK expression in mono-
cytes/macrophages is significantly higher than in hepatocytes or
adipocytes. Myeloid activation of NF-κB is correlated with functional
decline in models of HFD induced obesity and insulin resistance.
Indeed, here we show that ibrutinib treatment of mice fed a HFD
results in reduced activation of the NF-κB pathway in both the kidney
and liver, which as a consequence of HFD feeding have increased
accumulation of macrophages. Activation of NF-κB results in the pro-
duction of key components of the NLPR3 inflammasome pathway
including pro-caspase 1 and pro-IL-1β. Ablation of the NLRP3
inflammasome has been shown to improve glycaemic control in obese
mice by reducing caspase-1 cleavage and Il-1β/IL-18 activation
(Vandanmagsar et al., 2011). Here, we have demonstrated that treat-
ment with ibrutinib of mice fed a HFD attenuated the formation of
the NLRP3 complex and blocked the proteolytic cleavage of pro-
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caspase 1 to active caspase 1 resulting in attenuated production of IL-
1β in the liver and kidney.
One important consequence of having reduced metabolic
inflammation is improved glycaemic control. We demonstrate that
ibrutinib treatment of mice fed a HFD improved glycaemic control
(measured as OGTT) and lowered both terminal blood glucose and
insulin levels. Mechanistically, we also show that treatment with
ibrutinib of mice fed a HFD decreased the phosphorylation of
Ser307 on IRS-1 and increased activation of Akt and GSK-3β in the
liver. It should be noted that although phosphorylation of Ser307 is
a widely used marker of insulin resistance, it is not causative
in vivo (Copps et al., 2010). Some studies have reported that IKK-β
can also regulate insulin sensitivity through direct phosphorylation
of IRS-1 suggesting that there may also be a transcription-
independent mechanism of the NF-κB pathways in our model
(Arkan et al., 2005). Indeed, we show that mice fed a HFD and
treated with ibrutinib have less activation of IKK-β, which
correlates with a reduction in IRS-1 phosphorylation. Thus, we
have demonstrated for the first time a mechanistic link between
BTK inhibition and IKK-β/IRS-1 signalling in vivo.
Even with careful management of blood glucose and strategies
to lower circulating lipids, microvascular complications develop over
time in patients with T2D. These complications occur predominantly
in tissues where glucose uptake is insulin-independent, such as the
kidney, retina and vascular endothelium, as these tissues are exposed
to glucose levels close to blood glucose levels. The extent of inflam-
matory cell accumulation in the diabetic kidney has been associated
with the decline of renal function, suggesting a causative link
(Macisaac, Ekinci, & Jerums, 2014). We speculated that BTK is a
pivotal kinase in tissue resident macrophages needed for the
production of chemokines that recruit immune cells to sites of
inflammation. Tissue levels of key chemokines were reduced in the
liver, adipose tissue and kidney in mice fed a HFD and treated
with ibrutinib, including the chemokine CCL2 which is pivotal for
monocyte/macrophage recruitment. In many preclinical models of
diet induced obesity and microvascular disease genetic deletion or
pharmacological inhibition of CCR2 dramatically reduces macrophage
recruitment and protects the kidney from functional decline (Awad
et al., 2011; Sayyed et al., 2011). In the present study, ibrutinib
treatment significantly reduced macrophage accumulation due to
lower expression of CCL2 mRNA in the kidney of mice fed a HFD.
These results are consistent with previous data generated in
experimental models of diabetic nephropathy, where macrophage
accumulation is reduced in Ccl2−/− mice. Here, inhibition of BTK with
ibrutinib reduced both NF-κB and NLRP3 inflammasome activation in
the kidney, reduced classical histological markers of early diabetic
nephropathy, and protected mice from the development of
proteinuria. These data are consistent with other studies reporting
that targeting the inflammatory component of early stage diabetic
kidney disease improves functional outcome (Anders, 2016). Indeed,
individually targeting NF-κB and the NLRP3 inflammasome have
been shown to be efficacious in protecting against microvascular
disease in diabetes. While this accumulation of evidence from genetic
modifications in preclinical models validated this pathway as a thera-
peutic target, our study is unique in identifying an upstream
molecular target and demonstrating the efficacy of our approach
using an orally available, drug-repurposing candidate. Using an FDA
approved medicine, ibrutinib, we decreased NF-κB and NLRP3
inflammasome driven inflammation, improved glycaemic control and
elicited protection from microvascular damage in this model of diet-
induced metabolic inflammation.
In conclusion, the concept that the development of T2D is intrin-
sically linked to the extent of myeloid cell activation is emerging in the
field of diabetic medicine. Here, we demonstrate that BTK expression
and activation are increased in mice fed a HFD, and this significantly
correlated with monocyte/macrophage infiltration into the liver and
kidney. Therapeutic treatment with the FDA approved BTK inhibitor
ibrutinib not only reduced the extent of monocyte/macrophage
infiltration into the liver and kidney of mice fed a HFD but also atten-
uated the activation of NF-κB and the NLRP3 inflammasome.
Critically, we also demonstrated that treatment with ibrutinib reduced
systemic inflammation and resulted in improved glycaemic regulation,
lowering blood glucose and insulin levels, by restoring signalling
through IRS-1/Akt/GSK-3β. Improved glycaemic control also
protected mice fed a HFD from the development of hepatosteatosis
and proteinuria. Taken together, we have identified an FDA approved
medication that has many of the ideal properties of a candidate
medication for repurposing into the treatment of metabolic inflamma-
tion, in diseases such asType 2 diabetes.
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